The second-generation coronavirus vaccine designed in Argentina by researchers from the Leloir Institute Foundation (FIL) and Conicet -which It recently received funding to finalize the last preclinical stages before moving to human trials. The news was that it produced in mice a neutralizing immune capacity against various variants that did not decline in five months.
“We aim, like everyone else in the world, to achieve vaccines that with a single dose protect us for at least twelve months. The model would be something similar to the anti-flu, which today is tetravalent and protects us annually against different strains of the influenza virus “, he described today to Telam Osvaldo Podhajcer, project coordinator, head of the Laboratory of Molecular and Cellular Therapy (LTMC) at FIL and senior researcher at Conicet.
Podhajcer said that “with SARS-CoV-2 we should achieve something similar and that is why it is very important to continue researching and improving vaccines.”
“Now, with the results of the work, our CoroVaxG.3 vaccine is positioned as a possible candidate to move towards clinical trials,” he said.
At work, a single dose of CoroVaxG.3 applied to mice was able to stimulate a long-lasting immune response against the virus that lasted for five months without decaying. “This response was both humoral (antibodies) and cellular, which is what one seeks to achieve as an immunological memory response,” explained the specialist.
In addition, the researchers conducted in vitro studies with human cells to show that the vaccine is capable of inducing “in large quantities” the expression of the SARS-CoV-2 Spike protein in muscle cells (where the injection is received) and in human dendritic cells, which are the ones that trigger the memory immune response. “This allows for a powerful and long-lasting immune response,” Podhajcer noted.